NCT02277093View on ClinicalTrials.gov

Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 22, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

October 27, 2016

Conditions
Colorectal Cancer
Interventions
DRUG

Pacritinib

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

CTI BioPharma
All Listed Sponsors
collaborator

CTI BioPharma

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT02277093 - Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer | Biotech Hunter | Biotech Hunter